Drugs / Bifidobacterium Triple Viable Capsules
Bifidobacterium Triple Viable Capsules
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06836960 | Jun 2025 → Dec 2026 expected | enterocolitis | Jiujiang No.1 People's Hospital | Enrolling by invitation | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Bifidobacterium Triple Viable Capsules | “This intervention includes the oral administration of Bifidobacterium Triple Viable Capsules (0.5 g, three times daily) combined with Gegen Qinlian Tang (200 mL, twice daily)...” NCT06836960 ↗ |
| Modality | Other / unclassified | “a probiotics-only group (Bifidobacterium Triple Viable Capsules, three capsules twice daily)” NCT06836960 ↗ |
| Route | Oral | “This intervention includes the oral administration of Bifidobacterium Triple Viable Capsules (0.5 g, three times daily) combined with Gegen Qinlian Tang (200 mL, twice daily)...” NCT06836960 ↗ |